Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Graybug Vision
NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
NCT06439576 · Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, and more
NCT05562947 · Neovascular Age-related Macular Degeneration, nAMD
NCT05904028 · Neovascular Age-related Macular Degeneration
NCT07275840 · Neovascular Age-related Macular Degeneration
Retinal Consultants of Arizona
Gilbert, Arizona
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Midwest Eye Institute
Indianapolis, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions